Mechanisms of Sigma-2/TMEM97 Involvement in Cholesterol Metabolism.
HepG2
Sigma‐2/TMEM97
cholesterol
lipid metabolism
lysosome
rimcazole
siramesine
Journal
Journal of cellular biochemistry
ISSN: 1097-4644
Titre abrégé: J Cell Biochem
Pays: United States
ID NLM: 8205768
Informations de publication
Date de publication:
20 Sep 2024
20 Sep 2024
Historique:
revised:
21
08
2024
received:
12
12
2023
accepted:
25
08
2024
medline:
20
9
2024
pubmed:
20
9
2024
entrez:
20
9
2024
Statut:
aheadofprint
Résumé
Extensive research has focused on cellular cholesterol and its regulation, primarily due to its crucial physiological roles and its association with numerous diseases resulting from dysregulated homeostasis. Consequently, investigating cholesterol metabolism and the network of regulating proteins remains an ongoing challenge for biomedical research seeking new molecular targets to manage aberrant cholesterol levels in pathologic conditions. There is evidence that Sigma-2/TMEM97 receptor regulates cholesterol metabolism. However, the mechanisms remain incompletely understood to date. Therefore, this study aimed to employ a pharmacological approach based on selective Sigma-2/TMEM97 agonists, rimcazole and siramesine, to uncover the contribution of this receptor to cholesterol homeostasis. Our results indicate that Sigma-2/TMEM97 activation modulates cholesterol uptake by altering key proteins involved in, leading to free cholesterol and neutral lipids accumulation. This sheds light on potential mechanisms implied, contributing a new piece to the intricate puzzle of cholesterol metabolism homeostasis.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e30645Subventions
Organisme : This work has been supported by Together Strong NPC Foundation and Niemann-Pick Selbsthilfegruppe e.V. toVP, moreover by Excellence Departments, MUR-Italy, Grant/Award Numbers: ARTICOLO 1, COMMI 314-337 LEGGE 232/2016, ARTICOLO 1, awarded to Dept. of Science, University Roma Tre, Rome, Italy for 2023-2027, and Rome Technopole.
Informations de copyright
© 2024 Wiley Periodicals LLC.
Références
W. Y. Ho, H. Hartmann, and S.‐C. Ling, “Central Nervous System Cholesterol Metabolism in Health and Disease,” IUBMB Life 74, no. 8 (2022): 826–841, https://doi.org/10.1002/iub.2662.
C. Martini and V. Pallottini, “Cholesterol: From Feeding to Gene Regulation,” Genes & Nutrition 2, no. 2 (2007): 181–193, https://doi.org/10.1007/s12263-007-0049-y.
F. W. Pfrieger and N. Ungerer, “Cholesterol Metabolism in Neurons and Astrocytes,” Progress in Lipid Research 50, no. 4 (2011): 357–371, https://doi.org/10.1016/j.plipres.2011.06.002.
F. W. Pfrieger, “Role of Cholesterol in Synapse Formation and Function,” Biochimica et Biophysica Acta (BBA)—Biomembranes 1610, no. 2 (2003): 271–280, https://doi.org/10.1016/s0005-2736(03)00024-5.
M. G. Martín, F. Pfrieger, and C. G. Dotti, “Cholesterol in Brain Disease: Sometimes Determinant and Frequently Implicated,” EMBO Reports 15, no. 10 (2014): 1036–1052, https://doi.org/10.15252/embr.201439225.
L. Trapani, “Regulation and Deregulation of Cholesterol Homeostasis: The Liver as a Metabolic ‘Power Station’,” World Journal of Hepatology 4, no. 6 (2012): 184, https://doi.org/10.4254/wjh.v4.i6.184.
S. Member and M. Bruger, “Experimental Atherosclerosis; the Effect of Feeding Olive Oil on the Absorption and Deposition of Cholesterol,” Archives of Pathology 40 (1945): 373–375.
G. Luden, “The Blood Cholesterol—Its Importance, and the Value of Its Determination in Cancer Research,” Canadian Medical Association Journal 12, no. 3 (1922): 147–152.
V. Cartocci, M. Servadio, V. Trezza, and V. Pallottini, “Can Cholesterol Metabolism Modulation Affect Brain Function and Behavior?,” Journal of Cellular Physiology 232, no. 2 (2017): 281–286, https://doi.org/10.1002/jcp.25488.
M. Segatto, L. Leboffe, L. Trapani, and V. Pallottini, “Cholesterol Homeostasis Failure in the Brain: Implications for Synaptic Dysfunction and Cognitive Decline,” Current Medicinal Chemistry 21, no. 24 (2014): 2788–2802, https://doi.org/10.2174/0929867321666140303142902.
N. A. Colabufo, F. Berardi, C. Abate, M. Contino, M. Niso, and R. Perrone, “Is the σ2 Receptor a Histone Binding Protein?,” Journal of Medicinal Chemistry 49, no. 14 (2006): 4153–4158, https://doi.org/10.1021/jm0600592.
F. Bartz, L. Kern, D. Erz, et al., “Identification of Cholesterol‐Regulating Genes by Targeted RNAi Screening,” Cell Metabolism 10, no. 1 (2009): 63–75, https://doi.org/10.1016/j.cmet.2009.05.009.
C. Cantonero, P. J. Camello, G. M. Salido, J. A. Rosado, and P. C. Redondo, “TMEM97 Facilitates the Activation of SOCE by Downregulating the Association of Cholesterol to Orai1 in MDA‐MB‐231 Cells,” Biochimica et Biophysica Acta (BBA)—Molecular and Cell Biology of Lipids 1866, no. 6 (2021): 158906, https://doi.org/10.1016/j.bbalip.2021.158906.
A. Riad, C. Zeng, C.‐C. Weng, et al., “Sigma‐2 Receptor/TMEM97 and PGRMC‐1 Increase the Rate of Internalization of LDL by LDL Receptor Through the Formation of a Ternary Complex,” Scientific Reports 8, no. 1 (2018): 16845, https://doi.org/10.1038/s41598-018-35430-3.
L. Sanchez‐Pulido, and C. P. Ponting, “TM6SF2 and MAC30, New Enzyme Homologs in Sterol Metabolism and Common Metabolic Disease,” Frontiers in Genetics 5 (2014): 439, https://doi.org/10.3389/fgene.2014.00439.
Y.‐S. Cheng, T. Zhang, X. Ma, et al., “A Proteome‐Wide Map of 20(S)‐hydroxycholesterol Interactors in Cell Membranes,” Nature Chemical Biology 17, no. 12 (2021): 1271–1280, https://doi.org/10.1038/s41589-021-00907-2.
A. A. Behensky, I. E. Yasny, A. M. Shuster, S. B. Seredenin, A. V. Petrov, and J. Cuevas, “Stimulation of Sigma Receptors With Afobazole Blocks Activation of Microglia and Reduces Toxicity Caused by Amyloid‐β25–35,” Journal of Pharmacology and Experimental Therapeutics 347, no. 2 (2013): 458–467, https://doi.org/10.1124/jpet.113.208348.
H. M. Oyer, C. M. Sanders, and F. J. Kim, “Small‐Molecule Modulators of Sigma1 and Sigma2/TMEM97 in the Context of Cancer: Foundational Concepts and Emerging Themes,” Frontiers in Pharmacology 10 (2019): 1141, https://doi.org/10.3389/fphar.2019.01141.
C. Sánchez, J. Arnt, B. Costall, et al., “The Selective σ2‐Ligand Lu 28‐179 Has Potent Anxiolytic‐Like Effects in Rodents,” Journal of Pharmacology and Experimental Therapeutics 283, no. 3 (1997): 1323–1332.
P.‐P. Huang, W.‐Q. Zhu, J.‐M. Xiao, et al., “Alterations in Sorting and Secretion of Hepatic apoA5 Induce Hypertriglyceridemia Due to Short‐Term Use of Olanzapine,” Frontiers in Pharmacology 13 (2022): 935362, https://doi.org/10.3389/fphar.2022.935362.
C. Tonini, M. Colardo, B. Colella, et al., “Inhibition of Bromodomain and Extraterminal Domain (BET) Proteins by JQ1 Unravels a Novel Epigenetic Modulation to Control Lipid Homeostasis,” International Journal of Molecular Sciences 21, no. 4 (2020): 1297, https://doi.org/10.3390/ijms21041297.
Y. Zhang, H. Li, J. Wang, X. Geng, and J. Hai, “Meningioma‐Associated Protein 30 Accelerates the Proliferation and Invasion of Hepatocellular Carcinoma by Modulating Wnt/GSK‐3β/β‐Catenin Signaling,” Journal of Bioenergetics and Biomembranes 53, no. 1 (2021): 73–83, https://doi.org/10.1007/s10863-020-09864-2.
L. Tong, “Acetyl‐Coenzyme A Carboxylase: Crucial Metabolic Enzyme and Attractive Target for Drug Discovery,” Cellular and Molecular Life Sciences 62, no. 16 (2005): 1784–1803, https://doi.org/10.1007/s00018-005-5121-4.
J. D. Horton, “Sterol Regulatory Element‐Binding Proteins: Transcriptional Activators of Lipid Synthesis,” Biochemical Society Transactions 30, no. 6 (2002): 1091–1095, https://doi.org/10.1042/bst0301091.
A. J. Nelson, A. D. Sniderman, M. Ditmarsch, et al., “Cholesteryl Ester Transfer Protein Inhibition Reduces Major Adverse Cardiovascular Events by Lowering Apolipoprotein B Levels,” International Journal of Molecular Sciences 23, no. 16 (2022): 9417, https://doi.org/10.3390/ijms23169417.
R. J. Craven, H. N. Frazier, and O. Thibault, “Dependence of Glucose Transport on Autophagy and GAPDH Activity,” Brain Research 1776 (2022): 147747, https://doi.org/10.1016/j.brainres.2021.147747.
C. B. Wilcox, G. O. Feddes, J. E. Willett‐Brozick, L.‐C. Hsu, J. A. DeLoia, and B. E. Baysal, “Coordinate Up‐Regulation of TMEM97 and Cholesterol Biosynthesis Genes in Normal Ovarian Surface Epithelial Cells Treated With Progesterone: Implications for Pathogenesis of Ovarian Cancer,” BMC Cancer 7 (2007): 223, https://doi.org/10.1186/1471-2407-7-22.
D. Ebrahimi‐Fakhari, L. Wahlster, F. Bartz, et al., “Reduction of TMEM97 Increases NPC1 Protein Levels and Restores Cholesterol Trafficking in Niemann‐Pick Type C1 Disease Cells,” Human Molecular Genetics 25, no. 16 (2016): 3588–3599, https://doi.org/10.1093/hmg/ddw204.
V. Pallottini and F. W. Pfrieger, “Understanding and Treating Niemann–Pick Type C Disease: Models Matter,” International Journal of Molecular Sciences 21, no. 23 (2020): 8979, https://doi.org/10.3390/ijms21238979.
P. J. Espenshade and A. L. Hughes, “Regulation of Sterol Synthesis in Eukaryotes,” Annual Review of Genetics 41 (2007): 401–427, https://doi.org/10.1146/annurev.genet.41.110306.130315.
L. Trapani, M. Segatto, P. Ascenzi, and V. Pallottini, “Potential Role of Nonstatin Cholesterol Lowering Agents,” IUBMB Life 63, no. 11 (2011): 964–971, https://doi.org/10.1002/iub.522.
J. Perregaard, E. K. Moltzen, E. Meier, and C. Sanchez, “Sigma Ligands With Subnanomolar Affinity and Preference for the σ2 Binding Site. 1. 3‐(ω‐Aminoalkyl)‐1H‐indoles,” Journal of Medicinal Chemistry 38, no. 11 (1995): 1998–2008.
B. Zhitomirsky, A. Yunaev, R. Kreiserman, A. Kaplan, M. Stark, and Y. G. Assaraf, “Lysosomotropic Drugs Activate TFEB via Lysosomal Membrane Fluidization and Consequent Inhibition of mTORC1 Activity,” Cell Death & Disease 9, no. 12 (2018): 1191, https://doi.org/10.1038/s41419-018-1227-0.
M. Sardiello, M. Palmieri, and A. di Ronza, et al., “A Gene Network Regulating Lysosomal Biogenesis and Function,” Science 325, no. 5939 (2009): 473–477, https://doi.org/10.1126/science.1174447.